Order Article Reprints

Oosting LT, Franke K, Martin MV, Kloosterman WP, Jamieson JA, Glenn LA, de Jager MW, van Zanten J, Allersma DP, Gareb B. Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer. Pharmaceutics. 2022; 14(7):1515. https://doi.org/10.3390/pharmaceutics14071515

Oosting, Linette T., Katka Franke, Michael V. Martin, Wigard P. Kloosterman, Jennifer A. Jamieson, Laura A. Glenn, Miranda W. de Jager, Jacoba van Zanten, Derk P. Allersma, and Bahez Gareb. 2022. "Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer" Pharmaceutics 14, no. 7: 1515. https://doi.org/10.3390/pharmaceutics14071515

Oosting, L. T., Franke, K., Martin, M. V., Kloosterman, W. P., Jamieson, J. A., Glenn, L. A., de Jager, M. W., van Zanten, J., Allersma, D. P., & Gareb, B. (2022). Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer. Pharmaceutics, 14(7), 1515. https://doi.org/10.3390/pharmaceutics14071515